Worth reading
56In focus
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
This large-scale purchase of shares, etc.Counterpartyダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド・ピーエルシー（Nippon Active Value Fund PLC）, NAVF Select LLC
Disclosing companyASKA Pharmaceutical Holdings Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Target company
医療用医薬品事業、アニマルヘルス事業及び検査事業等
Procedures and assumptions
Management structure after acquisition趣旨説明書では、原則として現経営陣の経営方針に賛同・支持するとされ、ステークホルダーとの関係については「特にございません」とされている。
| Item | Details |
|---|---|
| Transaction name | This large-scale purchase of shares, etc. |
| Counterparty name | ダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド・ピーエルシー（Nippon Active Value Fund PLC）, NAVF Select LLC |
| Name of the Subject Company | ASKA Pharmaceutical Holdings Co.,Ltd. |
| Business Description of the Subject Company | 医療用医薬品事業、アニマルヘルス事業及び検査事業等 |
| Voting rights ownership percentage | Before 議決権比率約20.79％（2025年5月2日時点） → after 議決権総数の30％程度 |
| Management structure after acquisition | 趣旨説明書では、原則として現経営陣の経営方針に賛同・支持するとされ、ステークホルダーとの関係については「特にございません」とされている。 |
Items this document does not state (26)
Location of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.2025年7月1日に導入した対応方針に基づき、ダルトンらが提出した趣旨説明書の内容だけでは、株主・投資家の判断や取締役会の評価・検討に不十分となる可能性があるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.